AbbVie receives FDA approval for Parkinson’s drug Juvmo, a Cerevel acquisition asset

AbbVie has secured FDA approval for tavapadon, marketed as Juvmo, for the treatment of Parkinson’s disease in adults. The decision follows positive results from the Phase 3 TEMPO trial.

In the pivotal study, Juvmo demonstrated notable improvements in motor symptoms and extended periods of good symptom control compared with standard therapy. These outcomes formed the basis of the FDA’s approval.

The drug originated from AbbVie’s $8.7 billion purchase of Cerevel Therapeutics. While the acquisition’s antipsychotic candidate emraclidine failed in a mid‑stage schizophrenia trial, the Parkinson’s asset has now reached the market, offering a new option for patients and a potential revenue stream for the company.